Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410220 | 0.91 | KYNU (0.57) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL29678939 | 0.90 | KYNU (0.62) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL187849 | 0.90 | KYNU (0.62) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL269404 | 0.90 | KYNU (0.62) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL13798141 | 0.87 | KYNU (0.49) | KYNUELANEPRTN3KLK1CTSL | |
| SCHEMBL13435790 | 0.86 | KYNU (0.57) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL535707 | 0.86 | KYNU (0.57) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL1110994 | 0.85 | KYNU (0.56) | KYNUELANEPRTN3KLK1ATM | |
| SCHEMBL13798138 | 0.85 | KYNU (0.56) | KYNUELANEPRTN3KLK1ATM | |
| Lithium Ion SCHEMBL1110992 | 0.84 | KYNU (0.55) | KYNUELANEPRTN3KLK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | KYNU 3534/4885ELANE 992/4885PRTN3 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.